Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab biosimilar - Eli Lilly and Company/Innovent Biologics

Next Previous
X
Search
Drug Profile

Rituximab biosimilar - Eli Lilly and Company/Innovent Biologics

Alternative Names: HALPRYZA; IBI-301

Latest Information Update: 28 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Developer Eli Lilly and Company; Innovent Biologics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Granulomatosis with polyangiitis
  • No development reported B-cell lymphoma; Non-Hodgkin's lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2023 No recent reports of development identified for phase-I development in B-cell lymphoma in China (IV)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in China (IV)
  • 26 Aug 2022 Launched for Granulomatosis with polyangiitis in China (IV) before August 2022 (Innovent Biologics pipeline, August 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top